Friedberg noted that chemotherapy combined with an antibody remains a recommended treatment for patients with advanced-stage ...

Fifteen-year follow-up from the S0016 trial suggests that some patients with advanced-stage follicular lymphoma may be cured with standard chemoimmunotherapy, according to Dr. Jonathan W. Friedberg, ...

Cure rate of 42% estimated in cure modeling; highest rate seen for patients with low Follicular Lymphoma International Prognostic Index scores.

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A., and its Mexican affiliate, ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adults with relapsed or refractory ...

The shift toward dual-targeting bispecifics and the imminent arrival of highly efficacious triple combinations could shift the follicular lymphoma treatment space. The future treatment landscape for ...

Please provide your email address to receive an email when new articles are posted on . Epcoritamab-bysp in combination with lenalidomide and rituximab was approved for relapsed or refractory ...

At the recent American Society of Hematology (ASH) annual meeting, late-breaking phase III data demonstrated that adding tafasitamab (Monjuvi) to lenalidomide (Revlimid) and rituximab (Rituxan) ...

In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

Throughout the follicular phase, a single "dominant follicle" develops faster than the rest. This follicle (a fluid-filled sac in your ovary) then releases more estrogen into the body in preparation ...